Vancouver-based DiaGen AI Inc. and Montreal's Mila, Quebec's Artificial Intelligence Institute, announced a strategic partnership yesterday, aimed at accelerating the development of AI-powered therapeutic protein design for healthcare applications.
The collaboration brings together DiaGen's expertise in AI drug discovery with Mila's world-renowned machine learning research capabilities to tackle pressing challenges in healthcare, including cancer treatment and immune disorders.
DiaGen, founded in 2021, focuses on developing AI solutions for protein and peptide design, vaccine development, and diagnostics for health wellness and precision medicine. The company's team, led by Dr. Eldad Haber and Mohit Pandey, will work closely with Mila's research network to optimise therapeutic proteins for key properties such as stability, synthesisability, and target binding.